{"entity":{"id":"env-501","kind":"drug","name":"ENV-501","aka":[],"tldr":"ENV-501 is an experimental antibody-drug conjugate from Hummingbird Bioscience in phase 2 trials for melanoma, non-small-cell lung cancer and HR-positive / HER2-negative breast cancer, aimed at HER3.","summary":"ENV-501 is an antibody-drug conjugate developed by Hummingbird Bioscience. Its target is HER3. ClinicalTrials.gov describes the intervention as: ENV-501 is a HER3-targeted antibody-drug conjugate (ADC) with a humanized monoclonal antibody (mAb) conjugated with a chemotherapeutic payload via a linker. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in melanoma, non-small-cell lung cancer and HR-positive / HER2-negative breast cancer. The largest, NCT06956690, plans to enrol 180 participants with primary completion expected 2027-07. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of ENV-501","url":"https://clinicaltrials.gov/search?intr=ENV-501"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma","nsclc","breast-hr-positive"],"sections":[],"technologies":[],"targets":["her3"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06956690"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"ADC","mechanism":"Antibody-drug conjugate directed at HER3, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/env-501/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"her3","kind":"target","name":"HER3","route":"/targets/her3/"}],"trial":[{"id":"nct06956690","kind":"trial","name":"A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing ","route":"/trials/nct06956690/"}]}}